MIDECAMYCIN ACETATE-SUSCEPTIBILITY OF CLINICAL ISOLATES FROM DENTAL AND ORAL SURGICAL INFECTIONS

To investigate the clinical and bacteriological usefulness of orally administered midecamycin acetate (MOM), the susceptibility of clinical isolates to MOM, Mb-12 (the main metabolite of MOM), josamycin (JM), ampicillin (ABPC) and cephalexin (CEX) was determined. The results are summarized as follow...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1986/10/25, Vol.39(10), pp.2595-2600
Main Authors: DEGUCHI, KOICHI, YOKOTA, NOZOMI, TANAKA, SETSUKO, FUKAYAMA, SHIGEMI, NISHIMURA, YUKIKO, YOSHIHARA, HISAKO, ODA, SEIJI, MATSUMOTO, YOSHIHIRO, IKEGAMI, RYOSUKE, SATO, KUMIKO, FUKUMOTO, TORAO
Format: Article
Language:Japanese
Subjects:
Ampicillin - pharmacology
Bacteria, Aerobic - drug effects
Bacteria, Anaerobic - drug effects
Cephalexin - pharmacology
Humans
Leucomycins - pharmacology
Penicillin Resistance
Periodontal Diseases - microbiology
Surgical Wound Infection - microbiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 2600
container_issue 10
container_start_page 2595
container_title Japanese journal of antibiotics
container_volume 39
creator DEGUCHI, KOICHI
YOKOTA, NOZOMI
TANAKA, SETSUKO
FUKAYAMA, SHIGEMI
NISHIMURA, YUKIKO
YOSHIHARA, HISAKO
ODA, SEIJI
MATSUMOTO, YOSHIHIRO
IKEGAMI, RYOSUKE
SATO, KUMIKO
FUKUMOTO, TORAO
description To investigate the clinical and bacteriological usefulness of orally administered midecamycin acetate (MOM), the susceptibility of clinical isolates to MOM, Mb-12 (the main metabolite of MOM), josamycin (JM), ampicillin (ABPC) and cephalexin (CEX) was determined. The results are summarized as follows. 1. Antibacterial activities of MOM against aerobic Gram-positive cocci, B. catarrhalis, and anaerobic bacteria were inferior to those of JM by 2-fold, but superior to those of CEX. Activities of MOM against S. aureus, Bacteroides spp., Fusobacterium spp., Veillonella spp. were superior to those of ABPC and CEX. 2. Since serum and tissue concentrations of Mb-12 after 200mg administration in humans have been reported to be 1-2 μg/ml, it can be presumed that the causative bacteria would be eradicated by a usual dosage of MOM used in the present study. From these considerations, it is speculated that MOM may be successfully used in the treatment of dental and oral surgical infections.
doi_str_mv 10.11553/antibiotics1968b.39.2595
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_77258477</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77258477</sourcerecordid><originalsourceid>FETCH-LOGICAL-j190t-45ce5122daedd7bacf005c135b78ccf23406fde08c132ce95cb6315c2a265c4e3</originalsourceid><addsrcrecordid>eNpdkc1Og0AUhSdGU5vaRzDBjTvq_DDMsEQKOgkFU-iiKxyGQWloq0AXvr1T23Th5t6bc76cxbkAPCA4Q4hS8iR3Q1M2-6FRPfJcXs6IN8PUo1dgjBF3beowdg3GkLjcxoyjWzDt-6aEBDGOTcQIjIjrEMzpGLwvxDwM_MU6EInlB2Hu56GdrbIgfMvFs4hFvrbSyApikYjAjy2RpbFBMitapgtrHia5Ef1kbqVLc2Sr5csJS6IwyEWaZHfgppZtr6fnPQGrKMyDVztO_1B7gzw42A5VmiKMK6mripVS1RBShQgtGVeqxsSBbl1pyI2GlfaoKl2CqMISu1Q5mkzA4yn3q9t_H3Q_FNumV7pt5U7vD33BGKbcFGPA-zN4KLe6Kr66Ziu7n-JcifHjk7_pB_mhL77sTOGtLv63XxCvQPA4jz-4YOpTdoXekV9ktnuB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77258477</pqid></control><display><type>article</type><title>MIDECAMYCIN ACETATE-SUSCEPTIBILITY OF CLINICAL ISOLATES FROM DENTAL AND ORAL SURGICAL INFECTIONS</title><source>Alma/SFX Local Collection</source><creator>DEGUCHI, KOICHI ; YOKOTA, NOZOMI ; TANAKA, SETSUKO ; FUKAYAMA, SHIGEMI ; NISHIMURA, YUKIKO ; YOSHIHARA, HISAKO ; ODA, SEIJI ; MATSUMOTO, YOSHIHIRO ; IKEGAMI, RYOSUKE ; SATO, KUMIKO ; FUKUMOTO, TORAO</creator><creatorcontrib>DEGUCHI, KOICHI ; YOKOTA, NOZOMI ; TANAKA, SETSUKO ; FUKAYAMA, SHIGEMI ; NISHIMURA, YUKIKO ; YOSHIHARA, HISAKO ; ODA, SEIJI ; MATSUMOTO, YOSHIHIRO ; IKEGAMI, RYOSUKE ; SATO, KUMIKO ; FUKUMOTO, TORAO</creatorcontrib><description>To investigate the clinical and bacteriological usefulness of orally administered midecamycin acetate (MOM), the susceptibility of clinical isolates to MOM, Mb-12 (the main metabolite of MOM), josamycin (JM), ampicillin (ABPC) and cephalexin (CEX) was determined. The results are summarized as follows. 1. Antibacterial activities of MOM against aerobic Gram-positive cocci, B. catarrhalis, and anaerobic bacteria were inferior to those of JM by 2-fold, but superior to those of CEX. Activities of MOM against S. aureus, Bacteroides spp., Fusobacterium spp., Veillonella spp. were superior to those of ABPC and CEX. 2. Since serum and tissue concentrations of Mb-12 after 200mg administration in humans have been reported to be 1-2 μg/ml, it can be presumed that the causative bacteria would be eradicated by a usual dosage of MOM used in the present study. From these considerations, it is speculated that MOM may be successfully used in the treatment of dental and oral surgical infections.</description><identifier>ISSN: 0368-2781</identifier><identifier>EISSN: 2186-5477</identifier><identifier>DOI: 10.11553/antibiotics1968b.39.2595</identifier><identifier>PMID: 3643285</identifier><language>jpn</language><publisher>Japan: Japan Antibiotics Research Association</publisher><subject>Ampicillin - pharmacology ; Bacteria, Aerobic - drug effects ; Bacteria, Anaerobic - drug effects ; Cephalexin - pharmacology ; Humans ; Leucomycins - pharmacology ; Penicillin Resistance ; Periodontal Diseases - microbiology ; Surgical Wound Infection - microbiology</subject><ispartof>The Japanese Journal of Antibiotics, 1986/10/25, Vol.39(10), pp.2595-2600</ispartof><rights>Japan Antibiotics Research Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3643285$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DEGUCHI, KOICHI</creatorcontrib><creatorcontrib>YOKOTA, NOZOMI</creatorcontrib><creatorcontrib>TANAKA, SETSUKO</creatorcontrib><creatorcontrib>FUKAYAMA, SHIGEMI</creatorcontrib><creatorcontrib>NISHIMURA, YUKIKO</creatorcontrib><creatorcontrib>YOSHIHARA, HISAKO</creatorcontrib><creatorcontrib>ODA, SEIJI</creatorcontrib><creatorcontrib>MATSUMOTO, YOSHIHIRO</creatorcontrib><creatorcontrib>IKEGAMI, RYOSUKE</creatorcontrib><creatorcontrib>SATO, KUMIKO</creatorcontrib><creatorcontrib>FUKUMOTO, TORAO</creatorcontrib><title>MIDECAMYCIN ACETATE-SUSCEPTIBILITY OF CLINICAL ISOLATES FROM DENTAL AND ORAL SURGICAL INFECTIONS</title><title>Japanese journal of antibiotics</title><addtitle>Jpn. J. Antibiotics</addtitle><description>To investigate the clinical and bacteriological usefulness of orally administered midecamycin acetate (MOM), the susceptibility of clinical isolates to MOM, Mb-12 (the main metabolite of MOM), josamycin (JM), ampicillin (ABPC) and cephalexin (CEX) was determined. The results are summarized as follows. 1. Antibacterial activities of MOM against aerobic Gram-positive cocci, B. catarrhalis, and anaerobic bacteria were inferior to those of JM by 2-fold, but superior to those of CEX. Activities of MOM against S. aureus, Bacteroides spp., Fusobacterium spp., Veillonella spp. were superior to those of ABPC and CEX. 2. Since serum and tissue concentrations of Mb-12 after 200mg administration in humans have been reported to be 1-2 μg/ml, it can be presumed that the causative bacteria would be eradicated by a usual dosage of MOM used in the present study. From these considerations, it is speculated that MOM may be successfully used in the treatment of dental and oral surgical infections.</description><subject>Ampicillin - pharmacology</subject><subject>Bacteria, Aerobic - drug effects</subject><subject>Bacteria, Anaerobic - drug effects</subject><subject>Cephalexin - pharmacology</subject><subject>Humans</subject><subject>Leucomycins - pharmacology</subject><subject>Penicillin Resistance</subject><subject>Periodontal Diseases - microbiology</subject><subject>Surgical Wound Infection - microbiology</subject><issn>0368-2781</issn><issn>2186-5477</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><recordid>eNpdkc1Og0AUhSdGU5vaRzDBjTvq_DDMsEQKOgkFU-iiKxyGQWloq0AXvr1T23Th5t6bc76cxbkAPCA4Q4hS8iR3Q1M2-6FRPfJcXs6IN8PUo1dgjBF3beowdg3GkLjcxoyjWzDt-6aEBDGOTcQIjIjrEMzpGLwvxDwM_MU6EInlB2Hu56GdrbIgfMvFs4hFvrbSyApikYjAjy2RpbFBMitapgtrHia5Ef1kbqVLc2Sr5csJS6IwyEWaZHfgppZtr6fnPQGrKMyDVztO_1B7gzw42A5VmiKMK6mripVS1RBShQgtGVeqxsSBbl1pyI2GlfaoKl2CqMISu1Q5mkzA4yn3q9t_H3Q_FNumV7pt5U7vD33BGKbcFGPA-zN4KLe6Kr66Ziu7n-JcifHjk7_pB_mhL77sTOGtLv63XxCvQPA4jz-4YOpTdoXekV9ktnuB</recordid><startdate>198610</startdate><enddate>198610</enddate><creator>DEGUCHI, KOICHI</creator><creator>YOKOTA, NOZOMI</creator><creator>TANAKA, SETSUKO</creator><creator>FUKAYAMA, SHIGEMI</creator><creator>NISHIMURA, YUKIKO</creator><creator>YOSHIHARA, HISAKO</creator><creator>ODA, SEIJI</creator><creator>MATSUMOTO, YOSHIHIRO</creator><creator>IKEGAMI, RYOSUKE</creator><creator>SATO, KUMIKO</creator><creator>FUKUMOTO, TORAO</creator><general>Japan Antibiotics Research Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>198610</creationdate><title>MIDECAMYCIN ACETATE-SUSCEPTIBILITY OF CLINICAL ISOLATES FROM DENTAL AND ORAL SURGICAL INFECTIONS</title><author>DEGUCHI, KOICHI ; YOKOTA, NOZOMI ; TANAKA, SETSUKO ; FUKAYAMA, SHIGEMI ; NISHIMURA, YUKIKO ; YOSHIHARA, HISAKO ; ODA, SEIJI ; MATSUMOTO, YOSHIHIRO ; IKEGAMI, RYOSUKE ; SATO, KUMIKO ; FUKUMOTO, TORAO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j190t-45ce5122daedd7bacf005c135b78ccf23406fde08c132ce95cb6315c2a265c4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>1986</creationdate><topic>Ampicillin - pharmacology</topic><topic>Bacteria, Aerobic - drug effects</topic><topic>Bacteria, Anaerobic - drug effects</topic><topic>Cephalexin - pharmacology</topic><topic>Humans</topic><topic>Leucomycins - pharmacology</topic><topic>Penicillin Resistance</topic><topic>Periodontal Diseases - microbiology</topic><topic>Surgical Wound Infection - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DEGUCHI, KOICHI</creatorcontrib><creatorcontrib>YOKOTA, NOZOMI</creatorcontrib><creatorcontrib>TANAKA, SETSUKO</creatorcontrib><creatorcontrib>FUKAYAMA, SHIGEMI</creatorcontrib><creatorcontrib>NISHIMURA, YUKIKO</creatorcontrib><creatorcontrib>YOSHIHARA, HISAKO</creatorcontrib><creatorcontrib>ODA, SEIJI</creatorcontrib><creatorcontrib>MATSUMOTO, YOSHIHIRO</creatorcontrib><creatorcontrib>IKEGAMI, RYOSUKE</creatorcontrib><creatorcontrib>SATO, KUMIKO</creatorcontrib><creatorcontrib>FUKUMOTO, TORAO</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of antibiotics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DEGUCHI, KOICHI</au><au>YOKOTA, NOZOMI</au><au>TANAKA, SETSUKO</au><au>FUKAYAMA, SHIGEMI</au><au>NISHIMURA, YUKIKO</au><au>YOSHIHARA, HISAKO</au><au>ODA, SEIJI</au><au>MATSUMOTO, YOSHIHIRO</au><au>IKEGAMI, RYOSUKE</au><au>SATO, KUMIKO</au><au>FUKUMOTO, TORAO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MIDECAMYCIN ACETATE-SUSCEPTIBILITY OF CLINICAL ISOLATES FROM DENTAL AND ORAL SURGICAL INFECTIONS</atitle><jtitle>Japanese journal of antibiotics</jtitle><addtitle>Jpn. J. Antibiotics</addtitle><date>1986-10</date><risdate>1986</risdate><volume>39</volume><issue>10</issue><spage>2595</spage><epage>2600</epage><pages>2595-2600</pages><issn>0368-2781</issn><eissn>2186-5477</eissn><abstract>To investigate the clinical and bacteriological usefulness of orally administered midecamycin acetate (MOM), the susceptibility of clinical isolates to MOM, Mb-12 (the main metabolite of MOM), josamycin (JM), ampicillin (ABPC) and cephalexin (CEX) was determined. The results are summarized as follows. 1. Antibacterial activities of MOM against aerobic Gram-positive cocci, B. catarrhalis, and anaerobic bacteria were inferior to those of JM by 2-fold, but superior to those of CEX. Activities of MOM against S. aureus, Bacteroides spp., Fusobacterium spp., Veillonella spp. were superior to those of ABPC and CEX. 2. Since serum and tissue concentrations of Mb-12 after 200mg administration in humans have been reported to be 1-2 μg/ml, it can be presumed that the causative bacteria would be eradicated by a usual dosage of MOM used in the present study. From these considerations, it is speculated that MOM may be successfully used in the treatment of dental and oral surgical infections.</abstract><cop>Japan</cop><pub>Japan Antibiotics Research Association</pub><pmid>3643285</pmid><doi>10.11553/antibiotics1968b.39.2595</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0368-2781
ispartof The Japanese Journal of Antibiotics, 1986/10/25, Vol.39(10), pp.2595-2600
issn 0368-2781
2186-5477
language jpn
recordid cdi_proquest_miscellaneous_77258477
source Alma/SFX Local Collection
subjects Ampicillin - pharmacology
Bacteria, Aerobic - drug effects
Bacteria, Anaerobic - drug effects
Cephalexin - pharmacology
Humans
Leucomycins - pharmacology
Penicillin Resistance
Periodontal Diseases - microbiology
Surgical Wound Infection - microbiology
title MIDECAMYCIN ACETATE-SUSCEPTIBILITY OF CLINICAL ISOLATES FROM DENTAL AND ORAL SURGICAL INFECTIONS
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T20%3A45%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MIDECAMYCIN%20ACETATE-SUSCEPTIBILITY%20OF%20CLINICAL%20ISOLATES%20FROM%20DENTAL%20AND%20ORAL%20SURGICAL%20INFECTIONS&rft.jtitle=Japanese%20journal%20of%20antibiotics&rft.au=DEGUCHI,%20KOICHI&rft.date=1986-10&rft.volume=39&rft.issue=10&rft.spage=2595&rft.epage=2600&rft.pages=2595-2600&rft.issn=0368-2781&rft.eissn=2186-5477&rft_id=info:doi/10.11553/antibiotics1968b.39.2595&rft_dat=%3Cproquest_pubme%3E77258477%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-j190t-45ce5122daedd7bacf005c135b78ccf23406fde08c132ce95cb6315c2a265c4e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77258477&rft_id=info:pmid/3643285&rfr_iscdi=true